Navigation Links
Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
Date:8/21/2008

me to recurrence, patient-reported outcomes, plasma biomarkers, safety and tolerability.

The study is enrolling patients with all HCC histologies. Patients will be randomized to receive 400 mg of Nexavar twice daily or matching placebo for up to four years. The study will be conducted at more than 200 sites in North America, South America, Europe and the Asia-Pacific region, including Japan. For information about enrolling in the study, please visit http://www.clinicaltrials.gov.

Hepatocellular carcinoma is the most common form of liver cancer and is responsible for about 90 percent of the primary malignant liver tumors in adults. Liver cancer is the sixth most common cancer in the world and the third leading cause of cancer-related deaths globally. More than 600,000 cases of liver cancer are diagnosed worldwide each year (more than 400,000 in China, South Korea, Japan and Taiwan, 54,000 in the European Union, and 15,000 in the United States) and the incidence is increasing. In 2002, approximately 600,000 people died of liver cancer including approximately 370,000 in China, South Korea and Japan, 57,000 in the European Union, and 13,000 in the United States.(1,2)

Currently there are no adjuvant treatments with proven benefit in HCC and half of the patients who have undergone surgical resection or local ablation will see their tumors return within three years and 70 percent will see their tumors return within five years.(3)

Nexavar's Differentiated Mechanism

Nexavar targets both the tumor cell and tumor vasculature. In preclinical studies, Nexavar has been shown to target members of two classes of kinases known to be involved in both cell proliferation (growth) and angiogenesis (blood supply) -- two important processes that enable cancer growth. These kinases included Raf kinase, VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-B, KIT, FLT-3 and RET.

Nexavar is currently approved in m
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.; Bayer HealthCarePharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
2. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
3. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
4. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
5. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
6. Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen
7. Light Sciences Oncology Begins Clinical Trials of Litx Therapy in Patients with Enlarged Prostate
8. Catalyst Pharmaceutical Partners, Inc. Begins Enrollment for U.S. Phase II Clinical Trial of CPP-109 in Patients with Methamphetamine Addiction
9. Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases
10. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
11. European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014 Research and ... addition of the "Global Gynecological Devices ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... into wide categories based on their operations. ... of different gynecological conditions that affect the ...
(Date:9/19/2014)... , Sept. 19, 2014  The board of ... declared a quarterly cash dividend of $0.42 per share.  ... 17, 2014 to stockholders of record at the close ... AbbVie AbbVie is a global, research-based biopharmaceutical company formed ... is to use its expertise, dedicated people and unique ...
(Date:9/19/2014)... , Sept. 19, 2014  For Cloud Pharmaceuticals, ... design and development, partnering is an integral part ... to design new drugs and identify early stage, ... to further their development. The company also partners ... support this business model, Cloud Pharmaceuticals will be ...
Breaking Medicine Technology:Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 2Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 3Cloud Pharmaceuticals Announces Partnering Sessions and Presentation Schedule 2
... Mass. and SYDNEY, Dec. 2, 2010 HeartWare International, ... leading innovator of less invasive, miniaturized circulatory support technologies ... today announced that CEO Doug Godshall is scheduled to ... & Obesity Conference on Tuesday, December 7, 2010 at ...
... Dec. 2, 2010 Sagent Pharmaceuticals, Inc., a ... approval and launch of its topotecan hydrochloride for ... innovator,s patent expiry.  Sagent,s topotecan is available in ... latest product to feature Sagent,s proprietary PreventIV Measures™ ...
Cached Medicine Technology:HeartWare to Present at the Canaccord Genuity Cardio/Diabetes & Obesity Conference 2Sagent Pharmaceuticals Adds to Its Oncology Portfolio With Launch of Topotecan Hydrochloride for Injection 2
(Date:9/20/2014)... Weight Destroyer , a weight ... Michael Wren that has already helped tens of thousands ... conditions like high blood pressure, high cholesterol, and accelerated ... an investigative review. , “Weight Destroyer is totally ... by showing people what is truly effective when it ...
(Date:9/20/2014)... (PRWEB) September 20, 2014 Villa del ... resort did not experience any damage in relation to ... and activities available. , Hurricane Odile struck Cabo San ... wind, rain and powerful surf conditions. Located on the ... Islands of Loreto experienced some heavy rain, but no ...
(Date:9/20/2014)... On Monday, September 22, Loma Linda ... research grant from Hyundai Hope on Wheels at a ... located on 11234 Anderson St., in Loma Linda. The ... Associate Professor at Loma Linda University and Director of ... children. , Loma Linda University Medical Center ...
(Date:9/20/2014)... The avian flu that killed 160 harbor seals in ... drops and therefore poses a potential threat to humans, ... illnesses have been linked to the harbor seal virus, ... natural mutations to the avian H3N8 seal virus that ... droplets. Current seasonal flu vaccines wouldn,t help in ...
(Date:9/20/2014)... September 20, 2014 New PharmaPoint ... Market Analysis to 2023?. The asthma market saw ... it has become saturated with relatively efficacious standard ... (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and ... generic competition. However, the launch of seven novel ...
Breaking Medicine News(10 mins):Health News:Weight Destroyer: Review Exposes Michael Wren’s Guide to Effective Weight Loss and Improved Health 2Health News:Weight Destroyer: Review Exposes Michael Wren’s Guide to Effective Weight Loss and Improved Health 3Health News:Villa del Palmar at the Islands of Loreto Fully Functioning After Hurricane 2Health News:Villa del Palmar at the Islands of Loreto Fully Functioning After Hurricane 3Health News:Loma Linda University Medical Center Receives $250,000 Research Grant From Hyundai Hope On Wheels In Honor Of National Childhood Cancer Awareness Month 2Health News:Loma Linda University Medical Center Receives $250,000 Research Grant From Hyundai Hope On Wheels In Honor Of National Childhood Cancer Awareness Month 3Health News:Avian Flu In Harbor Seals Could Infect People 2Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 2Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 3Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 4
... French . Montreal, July 14, 2010 ... to a new study from the University of Montreal (Canada) ... Molecular Nutrition & Food Research , the investigation analyzed ... notably whether cashew extracts could improve the body,s response to ...
... psychologist at the University of Georgia shows that behavioral economic ... alcohol and other drugs. This method of studying how ... fairly new, but according to the study, it may well ... effective ways to defeat addictions. The research was published ...
... INDIANAPOLIS Pain and depression associated with cancer ... be significantly reduced through centralized telephone-based care management ... from the Regenstrief Institute and Indiana University School ... Depression (INCPAD) study combined automated calls with follow-up ...
... Doheny HealthDay Reporter , TUESDAY, July 13 (HealthDay ... last ",til death do you part" -- or if you ... game may reveal the hidden truth about your union, a ... flawed because it relies on asking the people involved how ...
... protein already used to treat diseases like multiple sclerosis, hepatitis ... patients, UT Southwestern Medical Center researchers have found. ... of a population of immune cells known to cause asthma. ... called T helper 2 cells, or Th2 cells. Under normal ...
... Gardner HealthDay Reporter , TUESDAY, July 13 (HealthDay ... than a decade ago that the blockbuster diabetes drug caused ... information, according to a report published Tuesday in The ... Avandia against its competitor, Actos, the drug company, then known ...
Cached Medicine News:Health News:New analysis may help clarify the role of craving in addiction 2Health News:New analysis may help clarify the role of craving in addiction 3Health News:Help is on the phone: Reducing pain and depression of cancer 2Health News:Word Games May Predict Life of Relationship 2Health News:Word Games May Predict Life of Relationship 3Health News:Interferon might help asthma patients breathe easier, UT Southwestern study suggests 2Health News:Avandia Heart Risks Buried by Drug Company: Report 2Health News:Avandia Heart Risks Buried by Drug Company: Report 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: